The Comprehensive Management of Parkinson's Disease PDF Download

Author: Matthew B. Stern
Publisher: Pma Publishing Corporation
ISBN: 9780893353162
Category : Medical
Languages : en
Pages : 205

View

Book Description

Author: Stewart A. Factor, DO
Publisher: Demos Medical Publishing
ISBN: 1934559873
Category : Medical
Languages : en
Pages : 858

View

Book Description
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Still the only major text on the subject, the completely revised and updated second edition of Parkinson's Disease: Diagnosis and Clinical Management comes at a time when specialists have made important advances in our understanding of the etiology, pathogenesis, investigation, and management of Parkinson's disease. The book includes 23 completely new chapters, and has updated information on: Genetics Pathology Biomarkers Pathogenesis Impulse control disorders in Parkinson's disease Updated outcome measures Complementary and alternative medicine for the treatment of Parkinson's disease Together the chapters form a comprehensive review of the many issues facing PD physicians today. Lucid and easily readable from beginning to end, each chapter may also stand on its own as a scholarly review of the individual subject. Each one is concisely written and heavily referenced for this purpose. The second edition of Parkinson's Disease: Diagnosis and Clinical Management provides a state-of-the-art review of where we've been, where we are now, and where we are going in treating this disease.

Author: Jonas H. Ellenberg
Publisher: CRC Press
ISBN: 9780824788230
Category : Medical
Languages : en
Pages : 600

View

Book Description
This comprehensive reference provides a detailed overview of current concepts regarding the cause of Parkinson's disease-emphasizing the issues involved in the design, implementation, and analysis of epidemiological studies of parkinsonism.

Author: J. Eric Ahlskog, PhD, MD
Publisher: Oxford University Press
ISBN: 0190231882
Category : Health & Fitness
Languages : en
Pages : 545

View

Book Description
The fundamental guide to the most effective treatments for Parkinson's Disease, from a Mayo Clinic doctor with thirty years of clinical and research experience. In this second edition follow-up to the extremely successful first edition, Dr. Ahlskog draws on thirty years of clinical experience to present the definitive guide to dealing with all aspects of Parkinson's Disease, from treatment options and side effects to the impact of the disease on caregivers and family. Dr. Ahlskog's goal is to educate patients so that they can better team up with their doctors to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information, distilled from his years of experience treating people with Parkinson's at the Mayo Clinic. In addition to providing a comprehensive account of Parkinson's medications, this book also examines additional aspects of treatment, such as the role of nutrition, exercise, and physical therapy. Although many commendable texts have been written on the subject of Parkinson's Disease, their discussions of treatment have not been in depth. Dr. Ahlskog sifts through aspects of the disease in order to give the reader a comprehensive sense of Parkinson's and the best available treatment options. With a broader understanding of the disease and the available options, patients are able to make more informed choices, and doctors are able to provide more tailored care. This book delivers hopeful, helpful, and extensive information to all parties concerned: patients, caregivers, and doctors. The ultimate guide to symptoms and treatment, this thoroughly updated second edition is the first place patients should turn for reliable, easy-to-grasp information on Parkinson's Disease.

Author: James Parkinson
Publisher:
ISBN:
Category : Parkinson's disease
Languages : en
Pages : 86

View

Book Description

Author: Maria Nord
Publisher: Linköping University Electronic Press
ISBN: 9176855570
Category :
Languages : sv
Pages : 72

View

Book Description
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.

Author: Cindy Levine
Publisher: Department of Health and Human Services Pu Ncy for Healthcare Res
ISBN: 9781587630880
Category : Evidence-based medicine
Languages : en
Pages : 306

View

Book Description

Author: Cheryl H. Waters
Publisher: Professional Communications
ISBN: 1932610456
Category : Medical
Languages : en
Pages : 289

View

Book Description
Provides the clinician with the concepts involved in effective management of Parkinson's disease. The diagnosis of PD is reviewed, as well as differential diagnosis. Pharmacologic management is the main focus of the book with detailed information on the efficacy of available drug therapies. Management of complications of PD and their therapy and surgical treatment options are reviewed.

Author: William J. Weiner
Publisher: JHU Press
ISBN: 0801885469
Category : Health & Fitness
Languages : en
Pages : 291

View

Book Description
Recent innovations, including deep brain stimulation and new medications, have significantly improved the lives of people with Parkinson’s disease. Nevertheless, medical, emotional, and physical challenges remain. The second edition of this accessible and comprehensive guide provides crucial information for managing this complex condition, including details on the use of medications, diet, exercise, complementary therapies, and surgery. The second edition includes new information about: • The genetic and hereditary pattern of the disease • Medications and uses of established medications • Other approaches to treating the symptoms of Parkinson’s • Juvenile-onset Parkinson’s disease • Normal pressure hydrocephalus • The effects of fluctuating hormones on disease symptoms • Fetal cell transplants and porcine cell transplants • The nutritional supplement Co-Enzyme Q10

Author: Lisette K. Bunting-Perry, MScN, RN
Publisher: Springer Publishing Company
ISBN: 0826103456
Category : Medical
Languages : en
Pages : 336

View

Book Description
"This is a wonderful resource for nurses and other healthcare professionals providing care for patients with Parkinson's Disease (PD)Ö.This unique book provides readers with access to multiple experts in the field and a wide variety of pertinent topics in the care of patients with PD. This is an excellent addition to the field and will be extremely useful for interdisciplinary teams caring for these patients." Score: 100, 5 stars --Doody's The incidence of Parkinson's is growing as the number of older adults making up the general population increases. The demand for nurses who specialize in the care of patients with movement disorders is also increasing and it is crucial that they have a comprehensive manual for patient care. Lisette Bunting-Perry and Gwyn Vernon have years of experience working with Parkinson's patients and have put together a team of internationally renowned clinicians who provide a truly comprehensive review of the information you need for the care of patients with this complex clinical profile. Comprehensive Nursing Care for Parkinson's Disease covers what is presently known about the disease and current evidence-based standards of care, including management through deep brain stimulation, palliative care for frail older adults with Parkinson's, medication management, nonmotor complications and psychosocial issues, and complementary and alternative approaches. This is an indispensable bedside companion in caring for those with Parkinson's as well as a much needed catalyst for the evaluation of future patient needs and the further development of comprehensive models of care.